左西孟旦用于心脏手术患者：目前的技术水平如何？
Levosimendan for heart-operated patients: what is the state of the art?
作者信息
Tagarakis Georgios I, Tsilimingas Nikolaos B
机构信息
Department of Cardiovascular and Thoracic Surgery, University of Thessaly, Larissa, Greece.
出版信息
Recent Pat Cardiovasc Drug Discov. 2009 Jan;4(1):22-4. doi: 10.2174/157489009787260052.
Acute heart failure is a common clinical problem faced in cardiac surgery operating rooms and intensive care units. Levosimendan, an inotropic and vasodilating agent used widely in cases of acute heart failure for "cardiological" patients, has not gained global acceptance in its application for heart-operated ones. Herein, we are presenting a series of studies and patents concerning this medication, which, in general, support the use of levosimendan during and after heart surgery, despite the relatively high cost of administration. However, trials with larger samples of patients have to be performed in order to definitively establish this medication as a routinely administered drug for acute congestive heart failure after heart surgery.
急性心力衰竭是心脏外科手术室和重症监护病房中常见的临床问题。左西孟旦是一种强心和血管舒张剂，广泛用于“心脏病”患者的急性心力衰竭病例，但在心脏手术患者中的应用尚未获得全球认可。在此，我们展示了一系列关于这种药物的研究和专利，总体而言，尽管给药成本相对较高，但这些研究和专利支持在心脏手术期间及术后使用左西孟旦。然而，必须进行更大样本量患者的试验，以便最终将这种药物确立为心脏手术后急性充血性心力衰竭的常规给药药物。
Zotero 插件